How an emergency department is organized to provide opioid-specific harm reduction and facilitators and barriers to harm reduction implementation: a systems perspective.
Acute care
Complex adaptive systems
Emergency department
Harm reduction
Opioid agonist treatment
Supervised consumption
Unregulated substance use
Withdrawal management
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
21 09 2023
21 09 2023
Historique:
received:
01
06
2023
accepted:
13
09
2023
medline:
25
9
2023
pubmed:
22
9
2023
entrez:
22
9
2023
Statut:
epublish
Résumé
The intersection of dual public health emergencies-the COVID-19 pandemic and the drug toxicity crisis-has led to an urgent need for acute care based harm reduction for unregulated opioid use. Emergency Departments (EDs) as Complex Adaptive Systems (CASs) with multiple, interdependent, and interacting elements are suited to deliver such interventions. This paper examines how the ED is organized to provide harm reduction and identifies facilitators and barriers to implementation in light of interactions between system elements. Using a case study design, we conducted interviews with Emergency Physicians (n = 5), Emergency Nurses (n = 10), and clinical leaders (n = 5). Nine organizational policy documents were also collected. Interview data were analysed using a Reflexive Thematic Analysis approach. Policy documents were analysed using a predetermined coding structure pertaining to staffing roles and responsibilities and the interrelationships therein for the delivery of opioid-specific harm reduction in the ED. The theory of CAS informed data analysis. An array of system agents, including substance use specialist providers and non-specialist providers, interacted in ways that enable the provision of harm reduction interventions in the ED, including opioid agonist treatment, supervised consumption, and withdrawal management. However, limited access to specialist providers, when coupled with specialist control, non-specialist reliance, and concerns related to safety, created tensions in the system that hinder harm reduction provision with resulting implications for the delivery of care. To advance harm reduction implementation, there is a need for substance use specialist services that are congruent with the 24 h a day service delivery model of the ED, and for organizational policies that are attentive to discourses of specialized practice, hierarchical relations of power, and the dynamic regulatory landscape. Implementation efforts that take into consideration these perspectives have the potential to reduce harms experienced by people who use unregulated opioids, not only through overdose prevention and improving access to safer opioid alternatives, but also through supporting people to complete their unique care journeys.
Sections du résumé
BACKGROUND
The intersection of dual public health emergencies-the COVID-19 pandemic and the drug toxicity crisis-has led to an urgent need for acute care based harm reduction for unregulated opioid use. Emergency Departments (EDs) as Complex Adaptive Systems (CASs) with multiple, interdependent, and interacting elements are suited to deliver such interventions. This paper examines how the ED is organized to provide harm reduction and identifies facilitators and barriers to implementation in light of interactions between system elements.
METHODS
Using a case study design, we conducted interviews with Emergency Physicians (n = 5), Emergency Nurses (n = 10), and clinical leaders (n = 5). Nine organizational policy documents were also collected. Interview data were analysed using a Reflexive Thematic Analysis approach. Policy documents were analysed using a predetermined coding structure pertaining to staffing roles and responsibilities and the interrelationships therein for the delivery of opioid-specific harm reduction in the ED. The theory of CAS informed data analysis.
RESULTS
An array of system agents, including substance use specialist providers and non-specialist providers, interacted in ways that enable the provision of harm reduction interventions in the ED, including opioid agonist treatment, supervised consumption, and withdrawal management. However, limited access to specialist providers, when coupled with specialist control, non-specialist reliance, and concerns related to safety, created tensions in the system that hinder harm reduction provision with resulting implications for the delivery of care.
CONCLUSIONS
To advance harm reduction implementation, there is a need for substance use specialist services that are congruent with the 24 h a day service delivery model of the ED, and for organizational policies that are attentive to discourses of specialized practice, hierarchical relations of power, and the dynamic regulatory landscape. Implementation efforts that take into consideration these perspectives have the potential to reduce harms experienced by people who use unregulated opioids, not only through overdose prevention and improving access to safer opioid alternatives, but also through supporting people to complete their unique care journeys.
Identifiants
pubmed: 37735432
doi: 10.1186/s12954-023-00871-1
pii: 10.1186/s12954-023-00871-1
pmc: PMC10515241
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
139Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Emerg Med. 2012 Aug;43(2):236-43
pubmed: 21719229
Int J Drug Policy. 2020 Sep;83:102896
pubmed: 32768156
Cochrane Database Syst Rev. 2013 Feb 28;(2):CD003409
pubmed: 23450540
Harm Reduct J. 2022 Feb 9;19(1):14
pubmed: 35139877
J Eval Clin Pract. 2018 Feb;24(1):285-292
pubmed: 29318709
Harm Reduct J. 2018 Sep 10;15(1):46
pubmed: 30200991
Harm Reduct J. 2021 Jun 5;18(1):60
pubmed: 34090473
Drug Alcohol Rev. 2019 Feb;38(2):169-176
pubmed: 30697852
Australas Psychiatry. 2005 Mar;13(1):33-9
pubmed: 15777410
Int J Integr Care. 2008;8:e68
pubmed: 19008987
Am J Emerg Med. 2019 Jan;37(1):143-150
pubmed: 30355476
Healthc Manage Forum. 2016 Jan;29(1):4-7
pubmed: 26656389
BMC Public Health. 2017 Apr 11;17(1):309
pubmed: 28399843
CJEM. 2020 Nov;22(6):768-771
pubmed: 33028446
J Am Coll Emerg Physicians Open. 2021 Mar 31;2(2):e12417
pubmed: 33817692
Ann Emerg Med. 2019 May;73(5):481-487
pubmed: 30616926
Cochrane Database Syst Rev. 2013 Jun 05;(6):CD009879
pubmed: 23740540
Crit Care Med. 2007 Feb;35(2 Suppl):S11-7
pubmed: 17242599
Ann Emerg Med. 2021 Dec;78(6):759-772
pubmed: 34353655
CJEM. 2019 Mar;21(2):226-234
pubmed: 29789030
J Adv Nurs. 2013 Apr;69(4):935-46
pubmed: 22776007
Emerg Med Australas. 2022 Aug;34(4):509-518
pubmed: 35021268
J Eval Clin Pract. 2018 Feb;24(1):308-313
pubmed: 28762632
CMAJ Open. 2021 Mar 17;9(1):E242-E251
pubmed: 33731425
Harm Reduct J. 2011 Jun 30;8:17
pubmed: 21718531
J Eval Clin Pract. 2018 Jun;24(3):629-634
pubmed: 29280244
PLoS One. 2019 Oct 24;14(10):e0224335
pubmed: 31648259
Nurs Outlook. 2007 Sep-Oct;55(5):232-241
pubmed: 17950117
Can Nurse. 2009 Apr;105(4):16-22
pubmed: 19435252
Harm Reduct J. 2017 Jun 5;14(1):32
pubmed: 28583121
Soc Sci Med. 2014 Mar;105:59-66
pubmed: 24508718
Cochrane Database Syst Rev. 2010 Aug 04;(8):CD003410
pubmed: 20687073
Int J Drug Policy. 2018 Mar;53:83-89
pubmed: 29289871
J Eval Clin Pract. 2018 Feb;24(1):301-307
pubmed: 28714561
Acad Emerg Med. 2021 May;28(5):542-552
pubmed: 33346926
J Eval Clin Pract. 2020 Oct;26(5):1552-1558
pubmed: 32496003
Ann Emerg Med. 2020 Jan;75(1):13-17
pubmed: 31229387
PLoS One. 2015 Oct 28;10(10):e0141594
pubmed: 26509447
Healthc Pap. 2003;3(3):29-35; discussion 66-71
pubmed: 12811085
Addiction. 2016 Jul;111(7):1177-87
pubmed: 27028542
AIDS Care. 2014 Jan;26(1):53-64
pubmed: 23656484
Lancet. 2011 Apr 23;377(9775):1429-37
pubmed: 21497898
Addiction. 2021 Jul;116(7):1892-1900
pubmed: 33339073
Harm Reduct J. 2019 Feb 13;16(1):16
pubmed: 30760261
CMAJ. 2018 Dec 17;190(50):E1466-E1467
pubmed: 30559278
J Viral Hepat. 2015 Oct;22(10):792-9
pubmed: 25586516
PLoS One. 2020 Mar 5;15(3):e0229713
pubmed: 32134973
BMC Res Notes. 2016 Oct 18;9(1):465
pubmed: 27756427
Harm Reduct J. 2016 Oct 7;13(1):28
pubmed: 27717368
J Healthc Qual. 2010 Jan-Feb;32(1):23-8
pubmed: 20151588
Drug Alcohol Depend. 2020 Nov 1;216:108202
pubmed: 32948372
Adm Policy Ment Health. 2005 Jan;32(3):211-20
pubmed: 15844845
Jt Comm J Qual Patient Saf. 2010 Apr;36(4):147-9
pubmed: 20402369
J Addict Med. 2019 Mar/Apr;13(2):104-112
pubmed: 30608266
Nurs Inq. 2019 Apr;26(2):e12286
pubmed: 30773745
Disabil Rehabil. 2006 May 15;28(9):587-93
pubmed: 16690588
J Eval Clin Pract. 2011 Jun;17(3):520-4
pubmed: 21496187
Subst Abus. 2020;41(4):519-525
pubmed: 31638862
J Addict Med. 2019 Mar/Apr;13(2):85-89
pubmed: 30608265
BMC Health Serv Res. 2018 Jul 20;18(1):570
pubmed: 30029638
CJEM. 2019 Jul;21(4):443-445
pubmed: 31333150
Harm Reduct J. 2017 May 18;14(1):28
pubmed: 28521829
CJEM. 2018 Jan;20(1):46-52
pubmed: 28918769
Addiction. 2016 Apr;111(4):685-94
pubmed: 26498577
Harm Reduct J. 2018 Feb 8;15(1):6
pubmed: 29422042
J Clin Nurs. 2010 Oct;19(19-20):2730-40
pubmed: 20846223
Soc Sci Med. 2010 Dec;71(11):1997-2004
pubmed: 20947232
Acad Emerg Med. 2022 Apr;29(4):442-455
pubmed: 34962682
BMC Med Res Methodol. 2011 Jun 27;11:100
pubmed: 21707982
Int J Drug Policy. 2021 Nov;97:103324
pubmed: 34153628
Harm Reduct J. 2022 Feb 5;19(1):13
pubmed: 35120536
Clin Nurse Spec. 2020 May/Jun;34(3):116-123
pubmed: 32250993